2023 Agenda

*Schedule is tentative and is subject to change.

Print Friendly, PDF & Email

Cellular Therapies and Novel Blood Products in Trauma and Critical Care – The Future of Transfusion Medicine

Monday, May 8

3:00 pm-7:00 pm
Registration Open – Alhambra Foyer
Badge and Materials Pick Up

4:00 pm-5:30 pm
Moderator/Speaker/Panel Briefing with A-V in Gen Session room – Alhambra Ballroom

6:30 pm-7:30 pm
Welcome Reception – Oasis Pool Bar
(Dinner on your own)

Tuesday, May 9 | Blood Products in Trauma and Critical Care

7:00 am-8:00 am
Breakfast – Kasbah Patio

7:00 am-5:30 pm
Registration Open – Alhambra Foyer
Badge and Materials Pick Up

8:00 am-6:00 pm
General Session – Alhambra Ballroom

8:00 am-8:10 am
Welcome & Introductions

  • Shibani Pati MD, PhD
    CTTACC Conference Chair
    Professor of Laboratory Medicine and Surgery, UCSF
    Scientific Director of Cellular Therapies

Session 1 | Whole Blood-The First Cell Therapy

This session will focus upon the pathophysiology of bleeding and coagulopathy in trauma. Focus areas will be on the utilization of whole blood in bleeding trauma patients and the optimization of resuscitation practice.

Moderator(s)

  • Martin Schreiber MD
    CTTACC Conference Co-Chair
    COL, US Army Reserve
    Professor of Surgery & Chief of Trauma, Critical Care & Acute Care Surgery
    Oregon Health & Science University (OHSU)

  • John Holcomb MD
    COL, USA, Ret.
    Professor of Surgery, Department of Surgery
    University of Alabama

8:10 am-8:30 am
The Pathophysiology of Trauma Induced Coagulopathy : Rationale for Whole Blood Resuscitation

  • Ernest “Gene” Moore MD, PhD
    Distinguished Professor of Surgery
    Vice Chairman for Research
    University of Colorado Denver, Anschutz Medical Campus

8:30 am-8:50 am
Norwegian Civilian Walking Blood Bank: Use of Whole Blood, and its Sustainability

  • Geir Strandenes MD
    Senior Medical Officer, Norwegian Naval Special Operation Commando
    Researcher, Department of Immunology and Transfusion Medicine
    Haukeland University Hospital, Bergen, Norway

8:50 am-9:10 am
Adjuncts to Whole Blood (Tranexamic Acid-TXA)

  • Jason Sperry MD, MPH
    Section Chief, Trauma Surgery
    Professor of Surgery and Critical Care
    Director of Acute Care Surgery Fellowship
    University of Pittsburgh

9:10 am-9:30 am
Fresh Warm Whole Blood vs Liquid Cold Stored Whole Blood/Comparisons and Differences

  • Andrew (Andre) Cap MD, PhD
    COL, USA
    Professor of Medicine
    Uniformed Services University of the Health Sciences
    Director of Research, Blood Research Program
    US Army Institute for Surgical Research

9:30 am-9:50 am
Regional Whole Blood Utilization in Texas-Logistics for Nationwide Implementation and Sustainability

  • Donald Jenkins, MD
    Col, USA, Ret.
    Professor of Surgery Uniformed Services University
    Professor/Clinical, Division of Trauma and Emergency Surgery
    Vice Chair for Quality, Department of Surgery UT Health San Antonio

9:50 am-10:10 am
Can We Make DCR ‘Perfect’ Every Time? Machine Learning and Real-Time Performance Improvement to Optimize Resuscitation

  • Jeremy Cannon MD, SM, FACS, COL, USAF
    Col, USAF Reserve
    Professor of Surgery

    Trauma Medical Director and Section Chief of Trauma
    Perelman School of Medicine, University of Pennsylvania

10:10 am-10:20 am
Question & Answer Panel | Session 1

10:20 am-10:40 am
Coffee Break – Alhambra Ballroom & Terrace
Visit Exhibits/Postersol

Session 2 | Blood Shortages and Adjunctive Therapies to Reduce Blood Utilization

This session will focus on the areas of blood shortages and how to manage and optimize blood utilization. The discussion panel will debate bloodless surgery and the ethics of rationing blood products in patients.

Moderator(s)

  • Beth Shaz MD, MBA
    Professor and Deputy Director of Marcus Center for Cellular Cures
    Duke University

  • Joseph Rappold MD
    CAPT, USN, Ret.
    Professor of Surgery
    Maine Medical Center Tufts University

10:30 am-10:45 am
Effect of Blood Shortages on Trauma Patient Management-Blood Equity

  • Martin Schreiber MD
    CTTACC Conference Co-Chair
    COL, USAR
    Professor of Surgery & Chief of Trauma, Critical Care & Acute Care Surgery
    Oregon Health & Science University

10:45 am-10:55 am
Walking Blood Banks in Times of Blood Shortages

  • John Holcomb MD
    COL, USA, Ret.
    Professor of Surgery, Department of Surgery
    University of Alabama

10:55 am-11:40 am
Panel Debate – Bloodless Surgery and the Ethics of Limiting Blood in Patients

Moderator(s)

  • Beth Shaz MD, MBA
    Professor and Deputy Director of Marcus Center for Cellular Cures
    Duke University
  • Joseph Rappold MD
    CAPT, USN, Ret.
    Professor of Surgery
    Maine Medical Center Tufts University

Panelist(s)

  • Andrew (Andre) Cap MD, PhD
    COL, USA
    Professor of Medicine
    Uniformed Services University of the Health Sciences
    Chief, Blood Research Program
    US Army Institute for Surgical Research

  • Pampee Young MD, PhD
    Chief Medical Officer, Biomedical Services, American Red Cross, Nashville, TN
    Adjunct Professor, Vanderbilt University, Cell and Developmental Biology
    Adjunct Professor, Pathology, Microbiology and Immunology

     

  • Martin Schreiber MD
    Chief, Radiological and Nuclear Countermeasures Branch,
    Division of Chemical, Biological, Radiological, and Nuclear Countermeasures
    Biomedical Advanced Research and Development Authority (BARDA)
    US Department of Health and Human Services

  • Ernest “Gene” Moore MD
    Distinguished Professor of Surgery
    Vice Chairman for Research
    University of Colorado Denver, Anschutz Medical Campus

  • Geir Strandenes MD
    Senior Medical Officer, Norwegian Naval Special Operation Commando
    Researcher, Department of Immunology and Transfusion Medicine
    Haukeland University Hospital, Bergen, Norway

11:40 am-12:40 pm
Lunch – Valencia Lawn

Session 3 | Cellular and Novel Therapeutics in Neurotrauma and Polytrauma

This session will focus on novel blood and cell therapies for traumatic brain injury (TBI) and spinal cord injury (SCI). Both clinical and pre-clinical studies will be presented.

Moderator(s)

  • Robert Mays PhD
    Vice President, Regenerative Medicine
    Head of Neurosciences, Athersys, Inc.

  • Hasan B. Alam MD
    Loyal and Edith Davis Professor and Chair, Department of Surgery
    Surgeon-in-Chief, Northwestern Memorial Hospital

1:00 pm-1:20 pm
Clinical Trial of Bone Marrow Mononuclear Cells for Severe TBI In Children

  • Charles S. Cox Jr.,MD
    The George and Cynthia Mitchell Distinguished Chair in Neurosciences
    Director, Children’s Program in Regenerative Medicine
    Professor, Department of Pediatric Surgery
    UTHealth Houston

1:20 pm-1:40 pm
Clinical Trial of Autologous adipose Derived MSCs for Chronic TBI

  • Charles S. Cox Jr.,MD
    The George and Cynthia Mitchell Distinguished Chair in Neurosciences
    Director, Children’s Program in Regenerative Medicine
    Professor, Department of Pediatric Surgery
    UTHealth Houston

1:40 pm-2:00 pm
Plasma for the Treatment of TBI: A Prospective Randomized Clinical Trial

  • Hasan Alam MD
    Chair, Department of Surgery
    Loyal and Edith Davis Professor of Surgery
    Professor of Surgery (Trauma and Critical Care) and Cell and Developmental Biology
    Northwestern University
    Surgeon-in-Chief at Northwestern Memorial Hospital

2:00 pm-2:20 pm
Clinical Trials of Stem Cells in Spinal Cord Injury

  • James Guest MD, PhD
    Clinical Professor, Department of Neurological Surgery
    Miller School of Medicine and Miami Project to Cure Paralysis
    University of Miami

2:20 pm-2:40 pm
Platelet Extracellular Vesicles and their Therapeutic Potential in TBI and Hemorrhagic Shock

  • Alpa Mahuvakar PhD
    Molecular Biologist and Neuroscientist, Department of Laboratory Medicine
    University California San Francisco

2:40 pm-2:50 pm
Question & Answer | Session 3

2:50 pm-3:00 pm
Coffee Break – Alhambra Ballroom & Terrace
Visit Exhibits/Posters

Session 4 | Platelet Biology and Novel Blood Products in Trauma and Hemorrhage

This session will discuss the pathophysiology of platelet and endothelial function in health and disease. Advances in novel platelet products and oxygen carriers will be presented.

Moderator(s)

  • Mike Fitzpatrick PhD
    COL, USA, Ret.
    Chief Scientific Officer
    Cellphire Therapeutics, Inc.

  • Ernest “Gene” Moore MD
    Distinguished Professor of Surgery
    Vice Chairman for Research
    University of Colorado Denver, Anschutz Medical Campus

3:00 pm-3:20 pm
Platelet Biogenesis in The Lung and Spleen During Homeostasis and Injury

  • Mark R. Looney MD
    Professor of Medicine and Laboratory Medicine
    University California San Francisco

3:20 pm-3:40 pm
Synthetic Platelets for Use in Trauma and Hemorrhage

  • Anirban Sen Gupta PhD
    Professor
    Case Western University, Biomedical Engineering

3:40 pm-4:00 pm
Microvascular Thrombosis – Innate Immune Signals that Drive Platelet Function

  • Matthew Neal MD
    Roberta G. Simmons Associate Professor of Surgery
    Co-Director, Trauma and Transfusion Medicine Research Center
    University of Pittsburgh

4:00 pm-4:10 pm
Intro to Whole Blood Substitute-DARPA

  • Jean-Paul Chretien MD, PhD
    CDR, Medical Corps, USN
    Program Manager
    Biological Technologies Office
    Defense Advanced Research Projects Agency (DARPA)

4:10 pm-4:30 pm
Synthetic Biology Meets Bio-Inspired Engineering: Path to a Whole Blood Analogue

  • Allan Doctor MD
    Professor of Pediatrics and Bioengineering
    Director, Center of Blood Oxygen Transport and Hemostasis
    CSO and Founding Partner, KaloCyte

4:30 pm-4:50 pm
Artificial Oxygen Carriers: Can We Use Them Now?

  • Jonathan Jahr MD, PhD DABA, FASA
    Professor Emeritus of Anesthesiology and
    Perioperative Medicine
    David Geffen School of Medicine at UCLA
    Ronald Reagan UCLA Medical Center

4:50 pm-5:10 pm
A Journey in Understanding Post-Injury Platelet Behavior

  • Lucy Kornblith MD
    Assistant Professor of Surgery and Lab Medicine, UCSF
    Division of General Surgery
    Trauma and Surgical Critical Care
    Zuckerberg San Francisco General Hospital

5:10 pm-5:30 pm
Biological Mechanisms and Treatment of the Endotheliopathy of Trauma with Novel Blood Products and Stem Cell Derived Therapies

  • Shibani Pati MD, PhD
    CTTACC Conference Chair
    Professor of Laboratory Medicine and Surgery, UCSF
    Scientific Director of Cellular Therapies

5:30 pm-5:40 pm
Question & Answer Panel | Session 4

5:40 pm-6:05 pm (includes Q&A)
The Therapeutic Potential for Integrative Medicine in Trauma and Critically Ill Patients

  • Virginia Von Schaefer MD
    Medical Director
    Integrative Oncology & Medicine Clinic – VVS MD, CA

6:05 pm-7:00 pm
Reception – Cortijo Plaza

7:00 pm-7:10 pm
Introduction of Keynote Speaker – Castillo Lucena

  • Kenneth Bertram MD, PhD
    Co-Chair CTTACC
    COL, USA, Ret.
    Clinical Product Development Officer
    Wake Forest University

7:10 pm-7:40 pm
2023 Keynote | MG (ret) Lester Martinez- Lopez MD

7:40 pm-9:00 pm
Dinner – Cortijo Plaza

Wednesday, May 10 | Regenerative Medicine and Cell Therapies for Trauma and Critical Care Medicine. Addressing Threat X (BARDA)

7:00 am-8:00 am
Breakfast – Kasbah Patio

7:00 am-5:30 pm
Registration Open – Alhambra Foyer
Badge and Materials Pick Up

8:00 am-8:10 am
Welcome & Introductions

  • Shibani Pati MD, PhD
    CTTACC Conference Chair
    Professor of Laboratory Medicine and Surgery, UCSF
    Scientific Director of Cellular Therapies

Session 5 | Novel Cell Therapies and Blood Products for the Treatment of COVID-19

This session will discuss the pathophysiology of COVID-19 as well as pre-clinical and clinical data on novel therapies (cell and blood) that have been investigated to mitigate outcomes in COVID-19 patients.

Moderator(s)

  • Andrew (Andre) Cap MD, PhD
    COL, US Army
    Professor of Medicine
    Uniformed Services University of the Health Sciences
    Chief, Blood Research Program
    US Army Institute for Surgical Research

8:05 am-8:25 am
The Immunology of COVID-19 and Long COVID

  • Clifford Lowell MD
    Distinguished Professor and Chair of Department of Laboratory Medicine
    University of California, San Francisco

8:25 am-8:45 am
Experiences and Lesson Learned in Caring for COVID-19 Patients in a Civilian Setting

  • Kevin Chung MD
    COL, Medical Corps, USA, Ret.
    CMO SeaStar Medical

8:45 am-9:05 am
Impact of COVID-19 in the Deployed Setting-Lessons Learned

  • Jennifer Gurney MD, FACS
    Director, Joint Trauma System
    COL, MC, US Army
    US Army Institute of Surgical Research
    Fort Sam Houston

9:05 am-9:25 am
MSCs in ARDS due to COVID-19, a Randomised Clinical Trial- the REALIST Trial

  • Danny McAuley MD
    Professor and Consultant in Intensive Care Medicine
    Queen’s University of Belfast and Royal Victoria Hospital, Belfast

9:25 am-9:45 am
Allogeneic Off-the-Shelf CAR NK Cell Therapy for Treating COVID-19 and Cancer

  • Jianhua Yu PhD
    Professor in the Department of Hematology & Hematopoietic Cell Transplantation
    City of Hope

9:45 am-10:05 am
Bone Marrow MSCs in Acute COVID-19 Data from a Multi-Center, Randomized Placebo Controlled Clinical Trial (STAT)

  • Michael Matthay MD
    Professor of Pulmonary Critical Care Medicine
    Research Lab Director, Acute Lung Injury and ARDS: Research and Clinical Trials
    Critical Care Specialist
    University of California San Francisco

10:05 am-10:25 am
Coffee Break – Alhambra Ballroom & Terrace
Visit Exhibits/Posters

10:25 am-10:45 am
Covid Convalescent Plasma for the Treatment of COVID-19 Patients

  • Michael J. Joyner MD
    Caywood Professor of Anesthesiology
    Department of Anesthesiology & Perioperative Medicine
    Mayo Clinic

10:45 am-11:05 am
Real World Data-Lessons Learned from CCP for COVID-19

  • Peter Marks MD, PhD
    Director of the Center for Biologics Evaluation and Research
    US FDA

11:05 am-11:15 am
Question & Answer Panel | Session 5

Session 6 | One Health Driving Translational Development for Novel Therapeutics

This session will explore the concept of One Health investigation in animals and how these studies can drive and advance translation of novel therapies to humans.

Moderator

  • Heather Pidcoke MD, PhD
    Chief Medical Research Officer, OVPR
    Joint Faculty, Dept. Clinical Sciences, CVMBS
    Colorado State University

11:15 am-11:30 am
One Health Driving Translational Development: The University Perspective

  • Tracy Webb DVM, PhD
    Research Scientist
    Colorado State University

11:30 am-11:45 am
One Health Driving Translational Development: The FDA Perspective

  • Lynne Boxer DVM
    Veterinary Medical Officer FDA
    Office of new Animal Drug Evaluation

11:45 am-12:00 pm
What is this Veterinary Data doing in My BLA? HBOCs/Lyophilized Blood Products/Stem Cells

  • Anne S. Hale DVM
    Chief Development Officer
    VetStem, Inc.

12:00 pm-12:15 pm
Initiatives in Veterinary Trauma: A Model for RDCR In Austere Environments

  • Kelly Hall
    DVM, MS, DACVECC
    Associate Professor, Critical Care Services
    Colorado State University
    Executive Director, ACVECC VetCOT

12:15 pm-12:25 pm
Question & Answer Panel | Session 6

12:25 pm-1:25 pm
Lunch – Kabash Patio

Session 7 | Regenerative Medicine and Stem Cells for Trauma and Critical Care

This session will focus on a number of regenerative and reparative approaches to mitigating outcomes in trauma and critical care medicine. CAR-T cell technology and advances will be discussed in the context of how they may be of potential use in injury and critical illness.

Moderator(s)

  • James Guest MD
    Professor of Neurological Surgery
    University of Miami, Miller School of Medicine
  • Michael Matthay MD
    Professor of Pulmonary Critical Care Medicine
    Research Lab Director, Acute Lung Injury and ARDS: Research and Clinical Trials
    Critical Care Specialist
    University of California, San Francisco

1:25 pm-1:45 pm
Enabling Technologies for Stem Cell Delivery to Wounds

  • Geoffrey Gurtner MD, FACS
    Chair, Department of Surgery
    Professor, Surgery
    Professor, Biomedical Engineering
    University of Arizona College of Medicine

1:45 pm-2:05 pm
Regenerating and Repairing Organ Damage Induced by Severe Injury with Novel Cryoprecipitate Products

  • Rosemary Kozar MD
    Professor, Surgery, Dept of Surgery
    Director of Translational Research, Shock Trauma Center
    Co-Director of STAR-ORC
    University of Maryland Baltimore

2:05 pm-2:25 pm
Bioprocessing and Ex Vivo Therapeutic Use of Mesenchymal Stromal Cells for Renal Repair

  • Biju Parekkadan PhD
    Associate Professor, Biomedical Engineering,
    Rutgers University

2:25 pm-2:45 pm
OMX, A Novel Oxygen Delivery Biotherapeutic for Treatment of Hemorrhagic Shock

  • Emin Maltepe, MD
    Professor Department of Pediatrics and Neonatology UCSF

2:45 pm-3:05 pm
Nanobody-Based CAR-T Cells and Potential Applications

  • Arun Wiita MD, PhD
    Associate Professor, Department of Laboratory Medicine
    Assistant Director, UCSF Clinical Cytogenetics Laboratory
    Director, UCSF Stephen and Nancy Grand Multiple Myeloma Translational Initiative Laboratory
    University of California, San Francisco

3:05 pm-3:25 pm
The Development of Smarter CART-T Cells

  • Franco Marincola MD
    Global Head of Cell Therapy Research
    Kite Pharma

3:25 pm-3:35 pm
Question & Answer Panel | Session 7

3:35 pm-3:55 pm
Coffee Break– Alhambra Ballroom & Terrace
Visit Exhibits/Posters

3:55 pm-4:15 pm
Antimicrobial Properties of Stem Cells in Wound Healing

  • Steve Dow MD
    Professor of Immunology
    Director of the Center for Immune and Regenerative Medicine
    Colorado State University

4:15 pm-4:30 pm
Human Placental Stem Cell-Based Combination Therapies for Prevention of Abdominal Adhesions

  • Samuel P. Carmichael II, MD
    Assistant Professor of Surgery
    Wake Forest School of Medicine – Baptist Medical Center
    North Carolina

4:30 pm-4:50 pm
Vascular Regeneration with Acellular Grafts

  • Luigi Pascarella, MD, FACS
    Professor of Surgery
    Vice Chair for Diversity, Equity, and Inclusion
    Director of Surgery Clerkship
    Division of Vascular Surgery
    Department of Surgery
    The University of North Carolina at Chapel Hill

4:50 pm-5:00 pm
Question & Answer Panel | Session 7

Session 8 | Product Development for Disaster Medicine – Threat X

Moderator(s)

  • Mary Homer, PhD
    Chief United States Radiological and Nuclear Countermeasures,
    Division of Chemical, Biological, Radiological, and Nuclear Countermeasures
    Biomedical Advanced Research and Development Authority (BARDA)

  • Mitchell Cohen MD
    Professor of Surgery and Vice Chair of Research
    University of Colorado

5:00 pm-5:15 pm
A Threat Agnostic Approach to Treating Injuries with Host Directed Therapeutics

  • Kimberly Hofmeyer, PhD
    Department of Health and Human Services
    BARDA

5:15 pm-5:30 pm
Animal Model Considerations for Development of Blood Products to Prevent, Mitigate, or Treat “Threat X”

  • Isabel Lauren Jackson, PhD
    Founding Principal
    True North BioPharma, LLC

  • Melanie Doyle-Eisele, PhD
    Senior Director Life Sciences/Laboratory Animal Sciences at Lovelace Biomedical

5:30 pm-5:45 pm
Rapid Development of Countermeasures to Address Threat X Using Human Organ Chips

  • Girija Goyal, PhD
    Senior Scientist
    Wyss Institute for Biologically Inspired Engineering at Harvard University

5:45 pm-6:00 pm
The Biology of Threat X: Coagulation, Inflammation, Immune and Endothelial Perturbations After Critical Injury and Illness. Implications for Generalized Countermeasures and Personalized Medicine

  • Mitchell Cohen, MD
    Professor of Surgery and Vice Chair of Research
    University of Colorado

6:00 pm- 6:10 pm
Question & Answer Panel | Session 8

6:10 pm-7:10 pm
Reception – Valencia Lawn
Visit Exhibits/Posters

7:10 pm-10:00 pm
Dinner – Valencia Lawn

Thursday, May 11 | Clinical Trial Design, Product Development and Sustaining Funding for Research

7:00 am-8:00 am
Breakfast – Kasbah Patio

7:00 am-12:00 pm
Registration Open – Alhambra Foyer
Badge and Materials Pick Up

8:00 am-8:05 am
Welcome & Introductions

  • Heather Pidcoke MD, PhD
    Chief Medical Research Officer, OVPR
    Joint Faculty, Dept. Clinical Sciences, CVMBS
    Colorado State University

Session 9 | Optimizing Clinical Trial Design to Support Advancement of Novel Therapies and Critical Care Medicine

Moderator(s)

  • Jason Sperry MD, MPH
    Section Chief, Trauma Surgery
    Andrew B. Peitzman Professor of Surgery
    Director, Acute Care Surgery Fellowship
    University of Pittsburgh

     

  • Charles S. Cox Jr.,MD
    The George and Cynthia Mitchell Distinguished Chair in Neurosciences
    Director, Children’s Program in Regenerative Medicine
    Professor, Department of Pediatric Surgery
    UTHealth Houston

8:05 am-8:25 am
Adaptive Platform Clinical Trial Design

  • Roger J. Lewis, MD, PhD
    Senior Medical Scientist, Berry Consultants, LLC
    Investigator, The Lundquist Institute
    Professor of Medicine, David Geffen School of Medicine at UCLA

8:25 am-8:45 am
Bayesian Trial Design in Trauma/ Community Consultation in EFIC Trials

  • Jan Jansen MBBS, PhD
    Professor | Division of Trauma & Acute Care Surgery
    Director | Center for Injury Science
    Associate Vice Chair for Clinical Trials | Department of Surgery
    University of Alabama at Birmingham

8:45 am-9:05 am
Gender Differences as Critical Considerations in Pre-Clinical and Clinical Development Pathways – What Took Us So Long?

  • Laura Ruse Brosch, RN, PhD
    COL, ANC, USA (ret)
    Assistant Vice President for Research Initiatives and Compliance
    Uniformed Services University of the Health Sciences

9:05 am-9:25 am
Long-term Outcomes Research in Trauma and Critical Care Medicine

  • Joe Cuschieri, MD
    Professor of Surgery and Lab Medicine
    Interim Chief of Surgery
    Trauma Medical Director at Zuckerberg San Francisco General Hospital and Trauma Center
    University of California San Francisco

9:25 am-9:45 am
The Evidence on Hemostatic Resuscitation for Children with Life Threatening Bleeding

  • Phil Spinella, MD, FCCM
    USA
    Professor in the Departments of Surgery and Critical Care Medicine
    Co-Director of the Trauma and Transfusion Medicine Research Center
    Associate Medical Director of the Center for Military Medicine Research
    University of Pittsburgh

9:45 am-10:10 am
Question & Answer Panel | Session 9

10:10 am-10:30 am
Coffee Break – Alhambra Ballroom & Terrace
Exhibits Close and Dismantle

Session 10 | Funding and Sustainability of Research Panel

This session will be focused on funding and sustainability of support for novel therapeutics in trauma and critical care. Points of discussion will include how to fund Phase 3 trials, how to advance translation to patients, and how to sustain research funding and support in this field through industry and federal agency partnerships.

Moderator(s)

  • Kenneth Bertram, MD, PhD
    Co-Chair CTTACC
    COL, USA, Ret.
    Clinical Product Development Officer
    Wake Forest University

     

     

  • Heather Pidcoke MD, PhD
    Chief Medical Research Officer, OVPR
    Joint Faculty, Dept. Clinical Sciences, CVMBS
    Colorado State University

10:30 am-10:45 am
Funding Through MRMC

  • Travis Polk, MD
    CAPT, USN
    Director, DoD Combat Casualty Care Research Program

    Chair, Joint Program Committee-6
    Director, Combat Casualty Care Research Program (CCCRP)
    US Army Medical Research and Development Command (USAMRDC)
    Defense Health Agency
    Ft Detrick, MD

10:45 am-11:30 am
Panel Discussion

  • Travis Polk, MD
    CAPT, USN
    Director, DoD Combat Casualty Care Research Program
    Chair, Joint Program Committee-6
    Director, Combat Casualty Care Research Program (CCCRP)
    US Army Medical Research and Development Command (USAMRDC)
    Defense Health Agency
    Ft Detrick, MD

     

  • Mary Homer, PhD
    Chief, Rad/Nuc Medical Countermeasures, CBRN Division
    Biomedical Advanced Research and Development Authority
    Department of Health and Human Services
    BARDA

     

  • Jean-Paul Chretien, MD, PhD
    Commander, Medical Corps, US Navy
    Program Manager
    Biological Technologies Office
    Defense Advanced Research Projects Agency (DARPA)

     

  • Terry M. Rauch, PhD, MPH, MBA
    Acting Deputy Assistant Secretary of Defense for Health Readiness Policy & Oversight OASD(HA)
    Defense Health Headquarters

     

  • Melinda Hamer, MD, MPH, FACEP
    LTC, USA
    Deputy Director, Operations
    Congressionally Directed Medical Research Programs
    Associate Professor of Military and Emergency Medicine at Uniformed Service University

Session 11 | Challenges of Product Development Talk Panel

This session will focus on the challenges of product development for novel cell therapies and blood products.

Moderator(s)

  • Becky Cap, MBA
    SVP, Business Development, Advanced Therapies
    BioBridge Global

     

  • Mary Homer, PhD
    Associate Professor of Clinical and Translational Sciences
    Director, Cellular Therapy Core
    Department of Pediatric Surgery
    McGovern Medical School of UTHealth

11:30 am-11:50 am
Challenges of Cell Therapy Product Development

  • Fabio Triolo, PhD
    Associate Professor of Clinical and Translational Sciences
    Director, Cellular Therapy Core
    Department of Pediatric Surgery
    McGovern Medical School of UTHealth

11:50 am-12:10 pm
Challenges of Novel Blood Product Development

  • Lisa Buckley, PhD
    Director of Clinical Trials and Regulatory Affairs
    OHSU/Velico Inc.

12:10 pm-12:30 pm
Challenges with Manufacturing Mesenchymal Stromal Cells for Clinical Trials

  • David Stroncek, MD
    Director, Center for Cellular Engineering, National Institutes of Health

12:30 pm- 12:35 pm
Concluding Remarks

  • Shibani Pati, MD, PhD
    CTTACC Conference Chair
    Professor of Laboratory Medicine, UCSF
    Scientific Director of Cellular Therapies

12:30 pm-1:30 pm
Lunch – Kabash Patio

Conference Adjourns

Presented by the University of California San Francisco Department of Laboratory Medicine

Presented by the Office of the Vice President of Research, the College of Veterinary Medicine and Biomedical Sciences, and the Infectious Disease Research Center.

SIGNUP FOR MORE INFORMATION

Questions? Email us at info@cttacc.org or call 303-238-0685